Press Release

IPGaia, Inc. and Tokyo Medical and Dental University Announce Master Collaborative Research and Development Agreement

July 20, 2022
 IPGaia, Inc., ("IPG") and Tokyo Medical and Dental University ("TMDU"), based in Tokyo, Japan, have entered into a Master Collaborative Research and Development Agreement ("this agreement") dated July 6th, 2022. This agreement establishes a formal framework for the incorporation of promising drug target leads from TMDU into IPG’s drug discovery platform. 

 The program enables TMDU to propose drug targets to IPG for identification and development of lead compounds or modalities with the goal of licensing clinical development candidates to pharmaceutical companies. IPG is soliciting drug target leads from a wide range of research institutions, including global academia and pharmaceutical companies, and is steadily expanding to the third institution, TMDU, to receive drug target leads from academia, both domestically and internationally. 

 For patients, personalized medicine holds great promise for the effective treatment and prevention of disease. For the pharmaceutical industry, personalized medicine provides the opportunity to achieve substantial clinical advances by tailoring treatments to the genes and personal circumstances that make every patient different. 

 “To create breakthrough healthcare innovation, TMDU is striving for enhancement of academic-industrial partnerships by leveraging TMDU’s high quality education, research or clinical assets.” Dr. Arinobu Tojo, Executive Vice President of TMDU states. “We hope the collaboration with IPG will further accelerate social implementation of TMDU’s innovative medical needs.”

 “It is our great pleasure and honor to have this agreement with TMDU which is one of the leading medical universities in Japan.” Yasu Yamaguchi, Ph.D., President and CEO of IPG states.  “This enables IPG to access to promising drug discovery seeds and to create highly innovative medicines.  In this sense, IPG moves forward to contributing to solving the global social issues such as high healthcare costs and to extending the healthy life expectancy.” 

[About IPG]

 IPG was established on October 26, 2021, as a wholly owned subsidiary of the Healthcare New Platform Fund where Whiz. Partners Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Atsushi Matsumura) has been the general partner. IPG will generate composition of matter patents for new chemical entities by conducting non-clinical research and development activities and make variety of transactions mainly with pharmaceutical companies. IPG has already concluded a comprehensive partnership agreement with Axcelead, Inc. and Axcelead Drug Discovery Partners, Inc. ( . By collaborating among the parties to build a next stage drug discovery platform, it would be possible to generate high quality innovative pharmaceuticals in a shorter period of time and lower cost. As for the pharmaceutical industry, the trend of the horizontal division of labor business model would be more accelerating. IPG plays a role as a platformer for creating pre-clinical stage innovative new medicines. 

[About TMDU]

 Tokyo Medical and Dental University was established as a national educational institution for dentistry on October 12, 1928, and currently located in the Yushima/Shoheizaka area of Tokyo, which is considered sacred ground for scholarship and learning in Japan. Since then, as Japan’s only comprehensive medical university and graduate school, TMDU has provided advanced medical treatment through a fusion of the medical and dental fields and worked to cultivate “professionals with knowledge and humanity,” thereby contributing to human health and the well-being of society.


IPGaia, Inc.
Eri Yokota; PR Manager 
Address:36F Atago Green Hills Mori Tower, 2-5-1 Atago, Minatoku, Tokyo Japan 
E-mail: contact (at)

TMDU Public Relations Office, General Coordination and Secretarial Section
E-mail: kouhou.adm (at) 

*Please change (at) in the e-mail addresses to @ when sending correspondence.